Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 7, 1998, Pages 2516-2522

  Blagosklonny, Mikhail V ^a   Giannakakou, Paraskevi ^a   Wojtowicz, Malgorzata ^a   Romanova, Larisa Y ^a   Ain, Kenneth B ^b   Bates, Susan E ^a   Fojo, Tito ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MITOMYCIN C; PACLITAXEL; PROTEIN P21; PROTEIN P53;

ADENOVIRUS; ANAPLASTIC CARCINOMA; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; CHEMOSENSITIVITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; THYROID CANCER; TUMOR DIFFERENTIATION; VIRUS CARCINOGENESIS;

EID: 0031786541     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.83.7.4984     Document Type: Article

References (22)

1. Sweeney PJ, Haraf DJ, Recant W, Kaplan EL, Yokes EE. 1996 Anaplastic carcinoma of the thyroid. Ann Oncol. 7:739-744.
2. Tan RK, Finley III RK, Driscoll D, Bakamjian V, Hicks Jr WL, Shedd DP. 1995 Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck. 17:41-48.
3. Wynford-Thomas D. 1997 Origin and progression of thyroid epithelial rumours: cellular and molecular mechanisms. Horm Res. 47:145-157.
4. Pollina L, Pacini F, Fontanini G, Vignati S, Bevilacqua G, Basolo F. 1996 bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br J Cancer. 73:139-143.
5. Dobashi Y, Sakamoto A, Sugimura H, et al. 1993 Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol. 17:375-381.
6. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. 1993 Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest. 91:1753-1760.
7. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest. 91:179-184.
8. Ito T, Seyama T, Mizuno T, et al. 1992 Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 52:1369-1371.
9. Nakamura T, Yana I, Kobayashi T, et al. 1992 p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res. 83:1293-1298.
10. Moretti F, Farsetti A, Soddu S, et al. 1997 p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene. 14:729-740.
11. Fagin JA, Tang SH, Zeki K, Di Lauro R, Fusco A, Gonsky R. 1996 Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res. 56:765-771.
12. Lowe SW, Ruley HE, Jacks T, Housman DE. 1993 p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:957-967.
13. O'Connor PM, Jackman J, Bae I, et al. 1997 Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57:4285-4301.
14. Blagosklonny MV, El-Deiry WS. 1996 In-vitro evaluation of p53-expressing adenovirus as an anti-cancel drug. Int J Cancer. 67:386-392.
15. Giannakakou P, Sackett D, Kang Y-K, et al. 1997 Paclitaxel-resistant human ovarian cancer cells have mutant b-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 272:17118-17125.
16. Blagosklonny MV, Toretskey J, Neckers L. 1995 Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene. 57:130-135.
17. Shi Y, Zou M, Fand NR, al-Sedairy ST. 1996 Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas. Br J Cancer. 74:1336-1341.
18. Milner J, Medcalf EA. 1991 Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell. 65:765-774.
19. Blaydes JP, Gire V, Rowson JM, Wynford-Thomas D. 1997 Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2. Oncogene. 14:1859-1868.
20. Kirn DH, Heise G, Mangold G, Von Hoff D. ONYX-015, a selectively replicating adenovirus, has antitumoral activity following IV administration alone and in combination with chemotherapy [Abstract 1564]. Proc of the American Society of Clinical Oncology. 1997; 437a.
21. Clayman GL, el-Naggar AK, Merritt J, et al. Adenovirus-mediated p53 gene transfer in a phase I trial of patients with advanced recurrent head and neck squamous carcinoma. Proc of the American Society of Clinical Oncology. 1997; 383a.
22. Morris JC, Kim CK, Padilla ML, Mechanick JI. 1997 Conversion of non-iodine-concentrating differentiated thyroid carcinoma metastasis into iodine-concentrating foci after anricancer chemotherapy. Thyroid. 7:63-66.